GLOBE LIFE INC. (GL) Stock News

Rosen Law Firm is investigating potential securities claims against Barclays PLC following allegations of materially misleading business information. The investigation was triggered by reports of Barclays' £600 million exposure to failed UK mortgage lender Market Financial Solutions Ltd, which caused Barclays' stock to decline 3.99% on February 27, 2026, and an additional 2.3% on March 2, 2026. Investors who purchased Barclays securities may be eligible to join a class action lawsuit.

Rosen Law Firm is reminding investors who purchased Primoris Services Corporation stock between August 5, 2025 and June 22, 2026 of the September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Primoris made false statements regarding its cost estimation and project oversight processes for fixed-price renewable energy projects, leading to systematic underestimation of costs and risks.

Rosen Law Firm has filed a class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The company allegedly failed to disclose these risks and was unable to achieve its 2025 guidance. Investors must move the court by September 22, 2026 to serve as lead plaintiff.

Rosen Law Firm has filed class action lawsuits against Microvast Holdings, Inc. and other companies on behalf of investors who purchased securities during specified periods. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and the completion of facility expansions. Investors who purchased securities during the class period may be eligible for compensation.

A securities class action lawsuit has been filed against First Solar, Inc. for allegedly making materially false and misleading statements regarding its capacity to manage U.S. tariff policy impacts and overstating projected performance. The lawsuit covers purchases between February 26, 2025 and February 24, 2026. The lead plaintiff deadline is August 24, 2026.

Vivos Inc. received FDA approval for its Investigational Device Exemption (IDE) to initiate a first-in-human feasibility study for RadioGel® at Mayo Clinic, targeting non-resectable papillary thyroid carcinoma patients. The company is expanding its animal therapy business with 17 certified clinics treating over 200 animals, establishing dual manufacturing facilities in the U.S. and India, and preparing for international clinical trial expansion with strong interest from multiple countries.

Rosen Law Firm is notifying investors in BitGo Holdings, Inc. (NYSE: BTGO) and GRAIL, Inc. (NASDAQ: GRAL) of ongoing securities class action lawsuits. BitGo investors who purchased shares during the IPO on January 22, 2026 or between January 22 and May 13, 2026 are urged to act before the August 7, 2026 lead plaintiff deadline. The lawsuit alleges that offering documents contained false statements regarding BitGo's risk exposure to declining digital asset prices and overstated business prospects. GRAIL investors have an August 4, 2026 deadline for the class action period covering May 13, 2025 to February 19, 2026.

A securities class action lawsuit has been filed against GRAIL, Inc. for allegedly providing misleading statements about its NHS-Galleri cancer screening trial. The lawsuit claims defendants concealed material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

Rosen Law Firm announces a securities class action lawsuit against Peabody Energy Corporation for allegedly providing false and misleading statements regarding its Centurion mine operations. The company significantly lowered guidance in March 2026, revealing that Q1 output would be approximately 250,000 tons instead of the previously estimated 700,000 tons due to mining commissioning challenges. Investors who purchased BTU stock between October 14, 2024 and May 4, 2026 may be eligible for compensation. The lead plaintiff deadline is August 24, 2026.

Shipping and logistics companies are tapping into the growing market of healthcare as cold chain and temperature-controlled facilities become more crucial.

Rosen Law Firm is encouraging investors who suffered losses exceeding $100,000 in Futu Holdings Limited to join a securities class action lawsuit. The lawsuit alleges that Futu made materially false statements and failed to disclose non-compliance with China Securities Regulatory Commission requirements, including conducting securities and futures business without proper licenses. The lead plaintiff deadline is August 25, 2026.

State Street's SPLB and Vanguard's VGLT offer different approaches to long-term bond investing. SPLB provides higher yields (5.5%) through corporate bonds but carries credit risk, while VGLT offers safer Treasury bonds with a lower expense ratio (0.03%) but lower yields (4.7%). SPLB has shown better 5-year returns and lower drawdowns, making it suitable for income-focused investors, while VGLT serves as a defensive safe-haven option.

Rosen Law Firm is notifying investors in Verra Mobility Corporation, Microsoft Corporation, and Disc Medicine, Inc. of upcoming deadlines to join securities class action lawsuits. The firm is seeking lead plaintiffs for cases involving alleged materially false statements and concealed material facts, with the primary deadline for Verra Mobility set for August 4, 2026.

A securities class action lawsuit has been filed against GPGI, Inc. (formerly CompoSecure, Inc.) for allegedly making materially false and misleading statements regarding the Husky acquisition. The lawsuit claims defendants overstated Husky's value, misrepresented revenue and EBITDA targets, and prioritized generating fees for Resolute Holdings over shareholder value. Investors who purchased Class A common stock between November 3, 2025 and May 6, 2026 may be eligible for compensation. The lead plaintiff deadline is September 14, 2026.

A multi-system study analyzing electronic health records from over 40,000 adults with alcohol use disorder found that GLP-1 receptor agonists (semaglutide and tirzepatide) were associated with 22-26% lower risk of alcohol-related hospitalization in patients with type 2 diabetes, and 32% lower risk in patients with obesity, compared to alternative treatments. Researchers emphasize the need for randomized clinical trials to establish causation.

Rosen Law Firm announces a securities class action lawsuit against Futu Holdings Limited, alleging the company made materially false statements and failed to disclose non-compliance with China Securities Regulatory Commission requirements. The lawsuit claims Futu conducted securities, public fund sales, and futures business in mainland China without proper licenses, leading to overstated financial results. Investors who purchased securities between May 24, 2023 and May 27, 2026 may be eligible for compensation, with a lead plaintiff deadline of August 25, 2026.

Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising in GLP-1 weight-loss drug marketing. Novo claims Lilly's ads unfairly compare outdated lower doses of Wegovy to higher doses of Zepbound, ignoring the FDA-approved 7.2 mg Wegovy dose (approved March 2025) which shows comparable weight loss results. Lilly maintains its ads are accurate based on the 2024 SURMOUNT-5 head-to-head trial. The lawsuit seeks an injunction, corrective advertising, and damages, though analysts believe the impact on both stocks is likely minimal.

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Rosen Law Firm has filed class action lawsuits against Planet Fitness, Insulet Corporation, and Photronics, Inc. on behalf of investors who purchased securities during specified periods. The lawsuits allege that these companies made materially false and misleading statements regarding business metrics and financial guidance. Investors have until September 14, 2026 to move the court to serve as lead plaintiff.

Eva Live Inc. (NASDAQ: GOAI) announced a Letter of Intent to acquire a controlling 51% interest in Airbeam Wireless Technologies for approximately $16 million, with an option to acquire the remaining 49%. The acquisition provides access to over 260 patents and advanced millimeter-wave semiconductor technology built on more than $150 million in cumulative R&D investment. Eva Live aims to combine Airbeam's wireless technology with its AI platform to develop next-generation communications for autonomous drone swarms, resilient military networks, smart cities, and satellite infrastructure, targeting a $3 trillion global opportunity.

Rosen Law Firm is urging investors who purchased Nano-X Imaging Ltd. securities between March 31, 2025 and April 17, 2026 to join a class action lawsuit. The lawsuit alleges that Nano-X made false statements about operational efficiency and product demand, while concealing poor manufacturing alignment, increased operating expenses, and significant cash burn that would require disruptive restructuring measures. The lead plaintiff deadline is August 11, 2026.

Fangzhou Inc. (HKEX: 06086), a leading AI-driven Internet healthcare provider, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its platform in collaboration with Novo Nordisk. The launch leverages Fangzhou's AI-enabled chronic disease management ecosystem to improve patient access to innovative diabetes treatments in China, the world's largest diabetes market with approximately 148 million adults living with diabetes.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Embecta Corp., where investors who purchased stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The lawsuit alleges that Embecta made false statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. The lead plaintiff deadline is August 17, 2026. Similar class actions are also mentioned for Calix, Inc. and Lucid Group, Inc.

Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.

Rosen Law Firm has filed class action lawsuits against GPGI, Inc. (formerly CompoSecure), Lucid Group, Inc., and Nano-X Imaging Ltd. on behalf of investors who suffered losses. The GPGI lawsuit alleges defendants made materially false statements regarding the Husky acquisition valuation and financial targets. Investors are encouraged to secure counsel before important deadlines.

A securities class action lawsuit has been filed against PicS N.V. following its January 2026 IPO. The lawsuit alleges that defendants made false and misleading statements regarding credit evaluation procedures, loan quality, and financial risks. Investors who purchased Class A common stock have until August 4, 2026 to serve as lead plaintiff.

Rosen Law Firm is urging investors in Black Rock Coffee Bar, Inc. (NASDAQ: BRCB) to join a securities class action lawsuit with an August 17, 2026 deadline to serve as lead plaintiff. The lawsuit alleges that defendants made materially false statements and failed to disclose that new store openings were cannibalizing existing revenue through 'sales transfer,' materially impacting financial results.

Rosen Law Firm is soliciting investors in Peabody Energy Corporation (BTU) who purchased stock between October 14, 2024 and May 4, 2026 to join a securities class action lawsuit. The lawsuit alleges that Peabody Energy made materially false and misleading statements regarding its Centurion mine operations, with the company significantly lowering guidance in March 2026 when it announced Q1 output would be approximately 250,000 tons versus previous estimates of 700,000 tons due to mining commissioning challenges.

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.